

Daftar Pustaka

- Adorno, M., Cordenonsi, M., Montagner, M., Dupont, S., Wong, C., Hann, B., *et al.* (2009). A Mutantp53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. *Cell*, 137 : 87–98.
- Ahmed, A. A., Etemadmoghadam, D., Temple, J., Lynch, A. G., Riad, M., Sharma, R., *et al.* (2010). Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. *J. Pathol.*, 22 : 49-56.
- Ang, H. C., Joerger, A. C., Mayer, S., & Fersht, A. R. (2006). Effects of common mutations on stability and DNA binding of full-length p53 compared with isolated core domains. *J. Biol. Chem.*, 281 : 21934–21941.
- Aschauer, L., & Muller, P. A. J. (2016). Novel targets and interaction partners of mutant p53 gain-of-function. *Biochem. Soc. Trans.*, 44 : 460-466.
- Ayed, A., Mulder, F. A., Yi, G. S., Lu, Y., Kay, L. E., & Arrowsmith, C. H. (2001). Latent and active p53 are identical in conformation. *Nat. Struct. Biol.*, 8 : 756–760.
- Bado, I., Nikolos, F., Rajapaksa, G., Wu, W., Castaneda, J., Krishnamurthy, S., *et al.* (2017). Somatic loss of estrogen receptor beta and p53 synergize to induce breast tumorigenesis. *Breast Cancer Res.*, 19 : 1-10.
- Bailey, S. T., Shin, H., Westerling, T., Liu, X. S., & Brown, M. (2012). Estrogen receptor prevents p53-dependent apoptosis in breast cancer. *PNAS*, 109 : 18060-18065.
- Baptiste, N., Friedlander, P., Chen, X., & Prives, C. (2002). The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. *Oncogene*, 21 : 9-21.
- Barlev, N. A., Liu, L., Chehab, N. H., Mansfield, K., Harris, K. G., Halazonetis, T. D., *et al.* (2001). Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. *Mol. Cell*, 8 : 1243–1254.
- Basse, N., Kaar, J. L., Settanni, G., Joerger, A. C., Rutherford, T. J., & Fersht, A. R. (2010). Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant. *Chem. Biol.*, 17 : 46-56.
- Baudino, T. A. (2015). Targeted cancer therapy: the next generation of cancer treatment. *Curr. Drug Discov. Technol.*, 12 : 3-20.
- Beckerman, R., & Prives, C. (2010). Transcriptional regulation by p53, *Cold Spring Harb Perspect Biol.*, 2 : 1-18.
- Bian, Y., & Xie, X-Q. (2018). Computational fragment-based drug design: current trends, strategies, and applications. *The AAPS*, 20 : 1-11.
- Bieging, K. T., & Attardi, L. D. (2012). Deconstructing p53 transcriptional networks in tumor suppression. *Trends Cell Biol.*, 22 : 97-106.

- Blanden, A. R., Yu, X., Loh, S. N., Levine, A. J., & Carpizo, D. R. (2015). Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer. *Drug Discov Today*, 20 : 1391-1397.
- Blanden, A. R., Yu, X., Wolfe, A. J., Gilleran, J. A., Augeri, D. J., O'Dell, R. S., *et al.* (2015). Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore. *Mol. Pharmacol.*, 87 : 825-831.
- Boeckler, F. M., Joerger, A. C., Jaggi, G., Rutherford, T. J., Vepintsev, D. B., & Fersht, A. R. (2008). Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. *PNAS*, 10 : 10360-10365.
- Borresen, A. L., Andersen, T. I., Eyfjord, J. E., Cornelis, R. S., Thorlacius, S., Borg, A., *et al.* (1995). TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. *Gene Chromosome Canc.*, 14 : 71-75.
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.*, 68 : 394-424.
- Brazdova, M., Navratilova, L., Tichy, V., Nemcova, K., Lexa, M., Hrstka, R., *et al.* (2013). Preferential binding of hot spot mutant p53 proteins to supercoiled DNA in vitro and in cells. *PLoS ONE*, 8 : 1-17.
- Brentnall, M., Rodriguez-Menocal, L., De Guevara, R. L., Cepero, E., & Boise, L. H. (2013). Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. *BMC Cell Biol.*, 14 : 1-9.
- Brooks, C. L., & Gu. W. (2003). Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. *Curr. Opin. Cell Biol.*, 15 : 164-171.
- Brosh, R., & Rotter, V. (2009). When mutants gain new powers: news from the mutant p53 field. *Nat. Rev. Cancer*, 9 : 701-713.
- Bullock, A. N., Henckel, J., DeDecker, B. S., Johnson, C. M., Nikolova, P. V., Proctor, M. R., *et al.* (1997). Thermodynamic stability of wild-type and mutant p53 core domain. *PNAS*, 94 : 14338-14342.
- Bullock, A. N., & Fersht, A. R. (2001). Rescuing the function of mutant p53. *Nat. Rev. Cancer.*, 1 : 68-76.
- Burgess, A., Chia, K. M., Haupt, S., Thomas, D., Haupt, Y., & Lim, E. (2016). Clinical Overview of MDM2/X-Targeted Therapies. *Front. Oncol.*, 6 : 1-7.
- Butler, J. S., & Loh, S. N. (2003). Structure, function, and aggregation of the zinc-free form of the p53 DNA binding domain. *Biochemistry*, 42 : 2396-2403.

- Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., *et al.* (2002). Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. *Nat. Med.*, 8 : 282-288.
- Cadwell, C., & Zambetti, G. P. (2001). The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. *Gene*, 277 : 15-30.
- Carr, A. M. (2000). Piecing together the p53 puzzle. *Science*, 287 : 1765-1766.
- Chargari, C., Leteur, C., Angevin, E., Bashir, T., Schoentjes, B., Arts, J., *et al.* (2011). Preclinical assessment of JNJ-26854165 (sardemetan), a novel tryptamine compound with radiosensitizing activity *in vitro* and in tumor xenografts. *Cancer Lett.*, 312 : 209-218.
- Chehab, N. H., Malikzay, A., Stavridi, E. S., & Halazonetis, T. D. (1999). Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. *PNAS*, 96 : 13777–13782.
- ChemAxon was used for energy minimization, MarvinSketch, 18.25, ChemAxon (<https://www.chemaxon.com>).
- Chene, P. (2003). Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. *Nat. Rev. Cancer*, 3 : 102-109.
- Chicas, A., Molina, P., & Bargonetti, J. (2000). Mutant p53 forms a complex with Sp1 on HIV-LTR DNA. *Biochem. Biophys. Res. Commun.*, 279 : 383–390.
- Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994). Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. *Science*, 265 : 346-355.
- Coates, J. (2000). *Interpretation of Infrared Spectra, A Practical Approach, Encyclopedia of Analytical Chemistry*. John Wiley & Sons Ltd, USA.
- Collingwood, S. P., Ratcliffe, A. J., Pryde, D., & Porter, R. (2015). *Recent disclosures of clinical candidates: Highlights from the society of medicines research symposium*. National heart & lung institute, london, UK, 40 : 81-91.
- Cooks, T., Pateras, I.S., Tarcic, O., Solomon, H., Schetter, A.J., Wilder, S., *et al.* (2013). Mutant p53 prolongs NF-kB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. *Cancer Cell*, 23 : 634–646.
- Craig, A. L., Burch, L., Vojtesek, B., Mikutowska, J., Thompson, A., & Hupp, T. R. (1999). Novel phosphorylation sites of human tumour suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers. *Biochem. J.*, 342 : 133–141.

- Dai, X., Cheng, H., Bai, Z., & Li, J. (2017). Breast cancer cell line classification and its relevance with breast tumor subtyping. *J. Cancer*, 16 : 3131-3141.
- Danovi, D., Meulmeester, E., Pasini, D., Migliorini, D., Capra, M., Frenk, R., *et al.* (2004). Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. *Mol. Cell Biol.*, 24 : 5835-5843.
- Dassault System BIOVIA. (2016). *Discovery Studio Visualizer*. V.17.2.0. San Diego: Dassault Systems.
- de Hoffmann, E., & Stroobant, V. (2007). *Mass Spectrometry: principles and applications*, 3rd Ed., John Wiley & Sons, Ltd, USA.
- Deng, X., Zhang, X., Tang, B., Liu, H., Shen, Q., Liu, Y., *et al.* (2018). Design, synthesis, and evaluation of dihydrobenzo[cd]indole-6-sulfonamide as TNF- α inhibitors. *Front. Chem.*, 6 : 1-1.
- Ding, Q., Zhang, Z., Liu, J-J., Jiang, N., Zhang, J., Ross, T. M., *et al.* (2013). Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. *J. Med. Chem.*, dx.doi.org/10.1021/jm400487c.
- Duffy, M. J., Synnott, N. C., & Crown, J. (2017). Mutant p53 as a target for cancer treatment. *Eur. J. Cancer*, 83 : 258-265.
- El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992). Definition of a consensus binding site for p53. *Nat. Genet.*, 1 : 45-49.
- Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., *et al.* (2015), Cancer incidence and mortality worldwide: Sources, methods, and major pattern in GLOBOCAN 2012. *Int. J. Cancer*, 136 : E359-E386.
- Fischer, M. (2017). Census and evaluation of p53 target genes. *Oncogene*, 1-14.
- Furet, P., Masuya, K., Kallen, J., Stachyra-Valat, T., Ruetz, S., Guagnano, V., *et al.* (2016). Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument. *Bioorg. Med. Chem. Lett.*, 26 : 4837-4841.
- Frank, A. K., Pietsch, E. C., Dumont, P., Tao, J., & Murphy, M. E. (2011). Wild-type and mutant p53 proteins interact with mitochondrial caspase-3. *Cancer Biol. Ther.*, 11 : 740-745.
- Freed-Pastor, W.A., Mizuno, H., Zhao, X., Langerød, A., Moon, S.H., Rodriguez-Barrueco, R., *et al.* (2012). Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. *Cell*, 148 : 244-258.
- Freed-Pastor, W. A., & Prives, C. (2012). Mutant p53: one name, many proteins. *Genes Dev.*, 26 : 1268-86.

- Freeman, J., Schmidt, S., Scharer, E., & Iggo, R. (1994). Mutation of conserved domain II alters the sequence specificity of DNA binding by the p53 protein. *EMBO J.*, 13 : 5393–5400.
- Friedler, A., Veprintsev, D. B., Freund, S. M., von Glos, K. I., & Fersht, A. R. (2005). Modulation of binding of DNA to the C-terminal domain of p53 by acetylation. *Structure*, 13 : 629-636.
- Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T., & Prives, C. (2001). A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. *Mol. Cell. Biol.*, 21 : 1874–1887.
- Gannon, J.V., Greaves, R., Iggo, R., & Lane, D. P. (1990). Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. *EMBO J.*, 9 : 1595–1602.
- Giaccia, A. J., & Kastan, M. B. (1998). The complexity of p53 modulation: emerging patterns from divergent signals. *Genes Dev.*, 12 : 2973–2983.
- Gohler, T., Jager, S., Warnecke, G., Yasuda, H., Kim, E., & Deppert, W. (2005). Mutant p53 proteins bind DNA in a DNA structure-selective mode. *Nucleic Acids Res.*, 33 : 1087–1100.
- Green, D. R., & Kroemer, G. (2009). Cytoplasmic functions of the tumor suppressor p53. *Nature*, 458 : 1-10.
- Grellety, T., Laroche-Clary, A., Chaire, V., Lagarde, P., Chibon, F., Neuville, A., *et al.* (2015). PRIMA-1^{MET} induces death in soft-tissue sarcomas cell independent of p53. *BMC Cancer*, 15 : 1-8.
- Gross, J. H. (2011). *Mass Spectrometry a textbook*, 2nd Ed., Springer, Germany.
- Halazonetis, T. D., & Kandil, A. N. (1993). Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. *EMBO J.*, 12 : 5057–5064.
- Hamada, M., Fujiwara, T., Hizuta, A., Gochi, A., Naomoto, Y., Takakura, N., *et al.* (1996). The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. *J. Cancer Res. Clin. Oncol.*, 122 : 360–365.
- Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of Cancer: The Next Generation. *Cell*, 144 : 646-674.
- Hanel, W., Marchenko, N., Xu, S., Yu, S. X., Weng, W., & Moll, U. (2013). Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. *Cell Death Differ.*, 20 : 898-909.
- Harris, S. L., & Levine, A. J. (2005). The p53 pathway: positive and negative feedback loops. *Oncogene*, 24 : 2899-2908.

- Hartenfeller, M., & Schneider, G. (2011). Enabling future drug discovery by de novo design. *WIREs Comput. Mol. Sci.*, 1 : 742-759.
- Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997). Mdm2 promotes the rapid degradation of p53. *Nature*, 387 : 296-299.
- Haupt, S., Raghu, D., & Haupt, Y. (2016). Mutant p53 drives cancer by subverting multiple tumor suppression pathways. *Front. Oncol.*, 6 : 1-7.
- Hayashi, Y. (1992). Overview of genotoxic carcinogens and non-genotoxic carcinogens. *Exp. Toxic. Pathol.*, 44 : 465-472.
- Helleday, T., Eshtad, S., & Nik-Zainal, S. (2014). Mechanism underlying mutational signature in human cancers. *Nat. Rev. Genet.*, 15 : 585-598.
- Heravi, M. R. P. H., & Piri, S. (2013). Efficient knoevenagel condensation reactions catalyzed by activated gel zirconium (IV) oxide. *J. Chem.*, 2013 : 1-5.
- Hollstein, M., Sidransky, D., Vogelstein, B., & Harrid, C. (1991). p53 mutations in human cancer. *Science*, 253 : 49-53.
- Honda, R., Tanaka, H., & Yasuda, H. (1997). Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. *FEBS Lett.*, 420 : 25-27.
- Huovinen, M., Loikkanen, J., Myllynen, P., & Vahakangas, K. H. (2011). Characterization of human breast cancer cell lines for the studies on p53 in chemical carcinogenesis. *Toxicol. In Vitro*, 25 : 1007-1017.
- Hwang, P. M., Bunz, F., Yu, J., Rago, C., Chan, T. A., Murphy, M. P., *et al.* (2001). Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. *Nat. Med.*, 7 : 1111-1117.
- Iggo, R., Gatter, K., Bartek, J., Lane, D., & Harris, A. L. (1990). Increased expression of mutant forms of p53 oncogene in primary lung cancer. *Lancet*, 335 : 675-679.
- Jin, S., & Levine, A. J. (2001). The p53 functional circuit. *J. Cell Sci.*, 114 : 4139-4140.
- Joerger, A. C., & Fersht, A. R. (2007). Structure-function-rescue: the diverse nature of common p53 cancer mutants. *Oncogene*, 26 : 2226-2242.
- Joerger, A. C., & Fersht, A. R. (2008). Structural biology of the tumor suppressor p53. *Annu. Rev. Biochem.*, 77 : 557-582.
- Joerger, A. C., Ang, H. C., & Fersht, A. R. (2006). Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. *PNAS*, 103 : 15056-15061.
- Joerger, A. C., Hwee, C. A., Veprintsev, D. B., Blair, C. M., & Fersht, A. R. (2005). Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations. *J. Biol. Chem.*, 280 : 16030-16037.
- Jones, G. (1967). The Knoevenagel Condensation. *Org. React.*, 15 : 204-599.

- Kaar, J. L., Basse, N., Joerger, A. C., Stephens, E., Rutherford, T. J., & Fersht, A. R. (2010). Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding. *Prot. Sci.*, 19 : 2267–2278.
- Kalo, E., Kogan-Sakin, I., Solomon, H., Bar-Nathan, E., Shay, M., Shetzer, Y., *et al.* (2012). Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species. *J. Cell Sci.*, 125 : 5578–5586.
- Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., *et al.* (2013). Mutational landscape and significance across 12 major cancer types. *Nature*, 502 : 333-339.
- Katsila, T., Spyroulias, G. A., Patrinos, G. P., & Matsoukas, M-T. (2016). Computational approaches in target identification and drug discovery. *Comput. Struct. Biotechnol J.*, 14 : 177-184.
- Kaustov, L., Yi, G. S., Ayed, A., Bochkareva, E., Bochkarev, A., & Arrowsmith, C. H. (2006). p53 transcriptional activation domain: a molecular chameleon?. *Cell Cycle*, 5 : 489-494.
- Kawamura, T., Suzuki, J., Wang, Y.V., Menendez, S., Morera, L.B., Raya, A., *et al.* (2009). Linking the p53 tumour suppressor pathway to somatic cell reprogramming. *Nature*, 460 : 1140–1144.
- Ke, X., & Shen, L. (2017). Molecular targeted therapy of cancer: The progress and future prospect. *Front. in Lab. Medicine*, 1 : 69-75.
- Keeler, J. (2002). *Understanding NMR Spectroscopy*. Wiley, Cambridge, UK.
- Kitayner, M., Rozenberg, H., Kessler, N., Rabinovich, D., Shaulov, L., Haran, T. E., *et al.* (2006). Structural basis of DNA recognition by p53 tetramers. *Mol. Cell*, 22 : 741-753.
- Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004). Docking and scoring in virtual screening for drug discovery: methods and applications. *Drug Discovery*, 3 : 935-949.
- Kluger, N., Jacot, W., Frouin, E., Rigau, V., Poujol, S., Dereure, O., *et al.* (2012). Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/ epirubicin/ cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients. *Ann. Oncol.*, 23 : 2879-2884.
- Knoevenagel, E. (1894) *cit.* Menegatti, R. (2012). Aspect for the Knoevenagel reaction. *Green Chemistry Environmentally Benign Approaches*. Dr. Mazaahir Kidwai (Ed.), ISBN: 978-953-51-0334-9.
- Ko, L. J., & Prives, C. (1996). p53: puzzle and paradigm. *Genes Dev.*, 10 : 1054–1072.
- Kogan, S., & Carpizo, D. (2016). Pharmacological targeting of mutant p53. *Transl. Cancer res.*, 5 : 698-706.

- Konduri, S. D., Medisetty, R., Liu, W., Kaipparettu, B. A., Srivastava, P., Brauch, H., *et al.* (2010). Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation. *PNAS*, 107 : 15081-15086.
- Kontoyianni, M. (2017). Docking and virtual screening in drug discovery. *in Proteomics for drug discovery: methods and protocols, methods in molecular biology*. 255-266. Springer Science + Business Media, USA.
- Kubbutat, M. H., Jones, S. N., & Vousden, K. H. (1997). Regulation of p53 stability by Mdm2. *Nature*, 387 : 299-303.
- Kumar, S. (2006). *Spectroscopy of organic compounds*. Dept. Of Chemistry, Guru Nanak Dev University, Amritsar, India.
- Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., *et al.* (1996). Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. *Science*, 274 : 948-953.
- Lakoma, A., Barbieri, E., Agarwal, S., Jackson, J., Chen, Z., Kim, Y., *et al.* (2015). The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma. *Cell Death Dis.*, 1 : 1-9.
- Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Soderqvist, M., Segerback, D., Bergman, J., *et al.* (2009). PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. *Cancer Cell*, 15 : 376-388.
- Lane, D. P. (1992). p53, guardian of genome. *Nature*, 358 : 15-16.
- Laptenko, O., & Prives, C. (2006). Transcriptional regulation by p53: one protein, many possibilities. *Cell Death Differ.*, 13 : 951-961.
- Laskowski, R. A., & Swindells, M. B. (2011). LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. *J. Chem. Inf. Model*, 51 : 2778-2786.
- Laurie, N. A., Donovan, S. L., Shih, C. S., Zhang, J., Mills, N., Fuller, C., *et al.* (2006). Inactivation of the p53 pathway in retinoblastoma. *Nature*, 444 : 61-66.
- Lee, S. J., Yum, Y. N., Kim, S. C., Kim, Y., Lim, J., Lee, W. J., *et al.* (2013). Distinguishing between genotoxic and non-genotoxic hepatocarcinogens by gene expression profiling and bioinformatic pathway analysis., *Sci.Rep.*, 3 : 1-9.
- Lehmann, B. D., & Pietenpol, J. A. (2012). Targeting Mutant p53 in human tumors. *J. Clin. Oncol.*, 30 : 3648-3650.
- Leroy, B., Fournier, J. L., Ishioka, C., Monti, P., Inga, A., Fronza, G., *et al.* (2013). The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. *Nucleic Acid Res.*, 41 : D962-D969.
- Levine, A. J., Hu, W., & Feng, Z. (2006). The P53 pathway: what questions remain to be explored?. *Cell Death Differ.*, 13 : 1027-1036.

- Levine, A. J., & Oren, M. (2009). The first 30 years of p53: growing ever more complex. *Nat. Rev. Cancer*, 9 : 749–758.
- Levine, A. J., Wu, M. C., Chang, A., Silver, A., Attiyeh, E. F., Lin, J., *et al.* (1995). The spectrum of mutations at the p53 locus: Evidence for tissue-specific mutagenesis, selection of mutant alleles, and a "gain of function" phenotype. *Ann. N. Y. Acad. Sci.*, 768 : 111-128.
- Li, D., Marchenko, N. D., Schulz, R., Fischer, V., Velasco-Hernandez, T., Talos, F., *et al.* (2011). Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. *Mol. Cancer Res.*, 9 : 577-88.
- Li, J. P. H., Adesina, A. A., Kennedy, E. M., & Stockenhuber, M. (2017). A mechanistic study of the Knoevenagel condensation reaction: new insights into the influence of acid and base properties of mixed metal oxide catalyst on the catalytic activity. *Phys. Chem. Chem. Phys.*, 19 : 26630-26644.
- Li, X-L., Zhou, J., Chen, Z-R, & Chng, W-J. (2015). p53 mutations in colorectal cancer-molecular pathogenesis and pharmacological reactivation. *World J. Gastroenterol.*, 21 : 84-93.
- Lill, N. L., Grossman, S. R., Ginsberg, D., DeCaprio, J., & Livingston, D. M. (1997). Binding and modulation of p53 by p300/CBP coactivators. *Nature*, 387 : 823–827.
- Lin, J., Chen, J., Elenbaas, B., & Levine, A. J. (1994). Several hydrophobic amino acids in the p53 aminoterminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. *Genes Dev.*, 8 : 1235–1246.
- Lin, Y., Ma, W., & Benchimol, S. (2000). Pidd, a new death-domain-containing protein, is induced by p53 and promotes apoptosis. *Nature Genet.*, 26 : 122–127.
- Liu, K., Ling, S., & Lin, W.C. (2011). TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73. *Mol. Cell. Biol.*, 31 : 4464–4481.
- Liu, J., Bai, R., Liu, Y., Zhang, X., Kan, J., & Jin, C. (2017). Isolation, structural characterization and bioactivities of naturally occurring polysaccharide-polyphenolic conjugates from medicinal plants-A review. *Int. J. Biol. Macromol.*, <https://doi.org/10.1016/j.ijbiomac.2017.10.097>.
- Liu, X., Wilcken, R., Joerger, A. C., Chuckowree, I. S., Amin, J., Spencer, J., *et al.* (2013). Small molecule induced reactivation of mutant p53 in cancer cells. *Nucleic Acids Res.*, 41 : 6034-6044.
- Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003). 5-fluorouracil: mechanisms of action and clinical strategies. *Nature Reviews*, 3 : 330-338.

- Lowe, S.W., & Lin, A. W. (2000). Apoptosis in cancer. *Carcinogenesis*, 21 : 485-495.
- Luo, J., Li, M., Tang, Y., Laszkowska, M., Roeder, R. G., & Gu, W. (2004). Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. *PNAS*, 101 : 2259-2264.
- Madar, S., Harel, E., Goldstein, I., Stein, Y., Kogan-Sakin, I., Kamer, I., *et al.* (2013). Mutant p53 attenuates the anti-tumorigenic activity of fibroblasts-secreted interferon beta. *PLoS ONE*, 8 : 1-11.
- Maley, C. C., Galipeau, P. C., Li, X., Sanchez, C. A., Paulson, T. G., Blount, P. L., *et al.* (2004). The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. *Cancer Res.*, 64 : 7629-7633.
- Marchenko, N. D., & Moll, U. M. (2014). Mitochondrial death function of p53. *Mol. Cell. Oncol.*, 1 : 1-8.
- Marine, J. C., & Lozano, G. (2010). Mdm2-mediated ubiquitylation: p53 and beyond. *Cell Death Differ.*, 17 : 93-102.
- Maslon, M. M., & Hupp, T. R. (2010). Drug discovery and mutant p53. *Trends Cell Biol.*, 20 : 542-555.
- McMurry, J. (2015). *Organic Chemistry with Biological Applications*, 3rd Ed. Cengage Learning, United States.
- Meek, D. W. (1999). Mechanism of switching on p53: a role for covalent modification?. *Oncogene*, 18 : 7666-7675.
- Mendrysa, S. M., O'Leary, K. A., McElwee, M. K., Michalowski, J., Eisenman, R. N., Powell, D. A., *et al.* (2006). Tumor suppression and normal aging in mice with constitutively high p53 activity. *Genes Dev.*, 20 : 16-21.
- Mirzayans, R., Andrais, B., Kumar, P., & Murray, D. (2017). Significance of wild-type p53 signaling in suppressing apoptosis in response to chemical genotoxic agents: impact on chemotherapy outcome. *Int. J. Mol. Sci.*, 18 : 1-20.
- Morton, J.P., Timpson, P., Karim, S. A., Ridgway, R. A., Athineos, D., Doyle, B., *et al.* (2010). Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. *PNAS*, 107 : 246-251.
- Muller, P. A. J., & Vousden, K. H. (2013). p53 mutations in cancer. *Nat. Cell Biol.*, 15 : 2-8.
- Muller, P. A., & Vousden, K. H. (2014). Mutant p53 in cancer: new functions and therapeutic opportunities. *Cancer Cell*, 25 : 304-317.
- Myers, M.C., Wang, J. L., Lera, J. A., Bang, J-k., Hara, T., Saito, S., *et al.* (2005). A new family of small molecules to probe the reactivation of mutant p53. *J. Am. Chem. Soc.*, 127 : 6152-6153.

- Narendran, A., Ganjavi, H., Morson, N., Connor, A., Barlow, J.W., Keystone, E., *et al.* (2003). Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth. *Exp. Hematol.*, 31 : 693–701.
- National Cancer Institute. (2017). NCI Dictionary of Cancer Terms. diakses dari www.cancer.gov. diakses pada 16 Juni 2017.
- Nguyen, D., Liao, W., Zeng, S. X., & Lu, H. (2017). Reviving the guardian of the genome: small molecule activators of p53. *Pharmacol. Ther.*, doi: 10.1016/j.pharmthera.2017.03.013.
- Oda, K., Arakawa, H., Tanaka, T., Matsuda, K., Tanikawa, C., Mori, T., *et al.* (2000). p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p3. *Cell*, 102 : 849-862.
- Olivier, M., Hollstein, M., & Hainaut, P. (2010). TP53 mutations in human cancers: origins, consequences, and clinical use. *Cold Spring Harb. Perspect. Biol.*, 2 : 1-17.
- Oren, M., Tal, P., & Rotter, V. (2016). Targeting mutant p53 for cancer therapy. *Aging*, 8 : 1159-1160.
- Owen, T. (2000). *Fundamentals of modern UV-Visible spectroscopy*. Agilent Technologies, Germany.
- Patocs, A., Zhang, L., Xu, Y., Weber, F., Caldes, T., Mutter, G.L., *et al.* (2007). Breast-cancer stromal cells with TP53 mutations and nodal metastases. *N. Engl. J. Med.*, 357 : 2543–2551.
- Pavia, D. L., Lampman, G. M., & Kriz, G. S. (2001). *Introduction to spectroscopy: a guide for students of organic chemistry*. Brooks/Cole Thomson Learning, USA.
- Peng, X., Zhang, M. Q. Z., Conserva, F., Hosny, G., Selivanova, G., Bykov, V. J. N., *et al.* (2013). APR-246/PRIMA-1^{MET} inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. *Cell Death Dis.*, 4 : 1-7.
- Pepper, J. W., Findlay, C. S., Kassen, R., Spencer, S. L., & Maley, C. C. (2009). Cancer research meets evolutionary biology. *Evol. Appl.*, 2 : 62-70.
- Pfeifer, G. P., Denissenko, M. F., Olivier, M., Tretyakova, N., Hecht, S. S., & Hainaut, P. (2002). Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. *Oncogene*, 21 : 7435–7451.
- Pretsch, E., Buhlman, P., & Badertscher, M. (2009). *Structure determination of organic compounds: table of spectral data*. 4th Ed., Springer, USA.
- Preudhomme, C., & Fenaux, P. (1997). The clinical significance of mutations of the P53 tumour suppressor gene in haematological malignancies. *Br J Haematol.*, 98 : 502–511.

- Prior, I. A., Lewis, P. D., & Mattos, C. (2012). A comprehensive survey of Ras mutations in cancer. *Cancer Res.*, 72 : 2457-2467.
- Punganuru, S. R., Madala, H. R., Venugopal, S. N., Samala, R., Mikelis, C., & Srivenugopal, K. S. (2016). Design and synthesis of a C7-aryl piperlongumine derivat with potent antimicrotubule and mutant p53-reactivating properties. *Eur. J. Med. Chem.*, 107 : 233-244.
- Ren, Z., Cao, W., & Tong, W., 2012, The Knoevenagel condensation reaction of aromatic aldehyde with malonitrile by grinding in the absence of solvents and catalyst, *Synth. Commun.*, **32**, 3475-3479.
- Ribeiro, C. J. A., Rodrigues, C. M. P., Moreira, R., & Santos, M. M. M. (2016). Chemical variations on the p53 reactivation theme. *Pharmaceuticals*, 9 : 1-33.
- Richards, S. A., & Hollerton, J. C. (2011). *Essential Practical NMR for Organic Chemistry*. John Wiley & Sons, United Kingdom.
- Riley, T., Sontag, E., Chen, P., & Levine, A. (2008). Transcriptional control of human p53- regulated genes. *Nat. Rev. Mol. Cell. Biol.*, 9 : 402-412.
- Ripphausen, P., Nisius, B., & Bajorath, J. (2011). State-of-the-art in ligand-based virtual screening. *Drug Discov. Today*, 16 : 372-376.
- Rivlin, N., Brosh, R., Oren, M., & Rotter, V. (2011). Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. *Genes Cancer*, 2 : 466-474.
- Rodrigues, N. R., Rowan, A., Smith, M. E. F., Kerr, I. B., Bodmer, W. F., Gannon, J. V., *et al.* (1990). p53 mutations in colorectal cancer. *PNAS*, 87 : 7555-7559.
- Roos, W., Baumgartner, M., & Kaina, B. (2004). Apoptosis triggered by DNA damage O6-methylguanine in human lymphocytes requires DNA replication and is mediated by p53 and Fas/CD95/Apo-1. *Oncogene*, 23 : 359-367.
- Sakamuro, D., Sabbatini, P., White, E., & Prendergast, G. C. (1997). The polyproline region of p53 is required to activate apoptosis but not growth arrest. *Oncogene*, 15 : 887-898.
- Sarig, R., Rivlin, N., Brosh, R., Bornstein, C., Kamer, I., Ezra, O., *et al.* (2010). Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells. *J. Exp. Med.*, 207 : 2127-2140.
- Sastrohamidjojo, H. (2001). *Spektroskopi*. Liberty, Yogyakarta.
- Scoumanne, A., & Chen, X. (2008). Protein methylation: a new mechanism of p53 tumor suppressor regulation. *Histol. Histopathol.*, 23 : 1143-1149.

- Sehouli, J., Fotopoulou, C., Erol, E., Richter, R., Reuss, A., Mahner, S., *et al.* (2015). Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: A metanalysis of four prospective randomised phase III trials with 5114 patients. *Eur. J. Cancer*, 51 : 825-832.
- Shaulsky, G., Goldfinger, N., Ben-Ze'ev, A., & Rotter, V. (1990). Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. *Mol. Cell Biol.*, 10 : 6565–6577.
- Shelling, A. N. (1997). Role of p53 in drug resistance in ovarian cancer. *Lancet*, 349 : 744–745.
- Shieh, S. Y., Ikeda, M., Taya, Y., & Prives, C. (1997). DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. *Cell*, 91 : 325–334.
- Shieh, S. Y., Ahn, J., Tamai, K., Taya, Y., & Prives, C. (2000). The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. *Genes Dev.*, 14 : 289-300.
- Shiloh, Y. (2003). ATM and related protein kinases: safeguarding genome integrity. *Nat. Rev. Cancer*, 3 : 155-168.
- Sigal, A., & Rotter, V. (2000). Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. *Cancer Res.*, 60 : 6788–6793.
- Silverstein, R. M., Webster, F. X., & Kiemle, D. J. (2005). *Spectrometric identification of organic compounds*. 7th Ed., John Wiley & Sons, USA.
- Sliwoski, G., Kothiwale, S., Meiler, J., & Lowe Jr., E. W. (2013). Computational methods in drug discovery. *Pharmacological Rev.*, 66 : 334-395.
- Smith, M. A., Gorlick, R., Kolb, A., Lock, R., Carol, H., Maris, J. M., *et al.* (2012). Initial testing of JNJ-26854165 (sardemetan) by the pediatric preclinical testing program. *Pediatr. Blood Cancer*, 59 : 329-332.
- Sobhani, M., Abdi, J., Manujendra, S. N., Chen, C., & Chang, H. (2015). PRIMA-1^{Met} induces apoptosis in Waldenstrom's Macroglobulinemia cells independent of p53. *Cancer Biol. Ther.*, 16 : 799-806.
- Song, H., Hollstein, M., & Xu, Y. (2007). p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. *Nat. Cell Biol.*, 9 : 573–580.
- Soussi, T., & Lozano, G. (2005). p53 mutation heterogeneity in cancer. *Biochem. Biophys. Res. Commun.*, 331 : 834-842.
- Stambolsky, P., Tabach, Y., Fontemaggi, G., Weisz, L., Maor-Aloni, R., Siegfried, Z., *et al.* (2010). Modulation of the vitamin D3 response by cancer-associated mutant p53. *Cancer Cell*, 17 : 273–285.

- Stavridi, E. S., Huyen, Y., Sheston, E. A., & Halazonetis, T. D. (2005). *The p53 tumor suppressor pathway and cancer: The three-dimensional structure of p53*. Springer Science+Business Media, New York.
- Strano, S., Fontemaggi, G., Costanzo, A., Rizzo, M.G., Monti, O., Baccarini, A., *et al.* (2002). Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. *J. Biol. Chem.*, 277 : 18817–18826.
- Stuart, B. (2004). *Infrared: fundamentals and applications*. John Wiley & Sons, Ltd, United States.
- Su, X., Chakravarti, D., Cho, M.S., Liu, L., Gi, Y.J., Lin, Y.L., *et al.* (2010). TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. *Nature*, 467 : 986–990.
- Sun, X.Z., Vinci, C., Makmura, L., Han, S., Tran, D., Nguyen, J., *et al.* (2003). Formation of disulfide bond in p53 correlates with inhibition of DNA binding and tetramerization. *Antioxid. Redox Signal.*, 5 : 655–665.
- Szilagyi, B., Skok, Z., Racz, A., Frlan, R., Ferenczy, G. G., Ilas, J., *et al.* (2018). Discovery of d-amino acid oxidase inhibitors based on virtual screening against the lid-open enzyme conformation. *Bioorg. Med. Chem. Lett.*, <https://doi.org/10.1016/j.bmcl.2018.04.048>.
- Tanaka, H., Arakawa, H., Yamaguchi, T., Shiraiishi, K., Fukuda, S., Matsui, K., *et al.* (2000). A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. *Nature*, 404 : 42–49.
- Taylor, W. R., & Stark, G. R. (2001). Regulation of the G2/M transition by p53. *Oncogene*, 20 : 1803-1815.
- Tessoulin, B., Descamps, G., Moreau, P., Maiga, S., Lode, L., Godon, C., *et al.* (2014). PRIMA-1^{Met} induces myeloma cell death independent of p53 by impairing the GSH/ROS balance. *Blood*, 124 : 1626-1636.
- Teufel, D. P., Freund, S. M., Bycroft, M., & Fersht, A. R. (2007). Four domains of p300 each bind tightly to a sequence spanning both transactivation subdomains of p53. *PNAS*, 104 : 7009-7014.
- Tovar, C., Graves, B., Packman, K., Filipovic, Z., Higgins, B., Xia, M., *et al.* (2013). MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. *Cancer Res.*, 73 : 2587-2597.
- Trot, O., & Olson, A. (2010). Autodock vina: improving the speed and accuracy of docking. *J. Comput. Chem.*, 31 : 455-461.
- Vaseva, A. V., Marchenko, N. D., Ji, K., Tsirka, S. E., Holzmann, S., & Moll, U. M. (2012). p53 opens the mitochondrial permeability transition pore to trigger necrosis. *Cell*, 149 : 1536-1548.

- Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., *et al.* (2004). In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. *Science*, 303 : 844-848.
- Velu, C. S., Niture, S. K., Doneanu, C. E., Pattabiraman, N., & Srivenugopal, K. S. (2007). Human p53 is inhibited by glutathionylation of cysteines present in the proximal DNA-binding domain during oxidative stress. *Biochemistry*, 46 : 7765–7780.
- Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., *et al.* (2007). Restoration of p53 function leads to tumour regression in vivo. *Nature*, 445 : 661-665.
- Villoutreix, B. O., Eudes, R., & Miteva, M. A. (2009). Structure based virtual ligand screening: recent success stories. *Comb. Chem. High Throughput Screen*, 12 : 1000-1016.
- Vogelstein, B., Lane D., & Levine, A. J. (2000). Surfing the p53 network. *Nature*, 408 : 307–310.
- Vousden, K. H., & Lu, X. (2002). Live or let die: the cell's response to p53. *Nature*, 2 : 594- 604.
- Wade, Jr., L. G. (2006). *Organic chemistry*, 6th Ed., Pearson Prentice Hall, USA.
- Wahl, G. M., Linke, S. P., Paulson, T. G., & Huang, L. C. (1997). Maintaining genetic stability through TP53 mediated checkpoint control. *Cancer Surv.*, 29 : 183–219.
- Walsh, J. G., Cullen, S. P., Sheridan, C., Luthi, A. U., Gerner, C., & Martin, S. J. (2008). Executioner caspase-3 and caspase-7 are functionally distinct proteases. *PNAS.*, 105 : 12815-12819.
- Wang, Y., Reed, M., Wang, P., Stenger, J. E., Mayr, G., Anderson, M. E., *et al.* (1993). p53 domains: identification and characterization of two autonomous DNA-binding regions. *Genes Dev.*, 7 : 2575-2586.
- Wang, P. L., Sait, F., & Winter, G. (2001). The “wildtype” conformation of p53: epitope mapping using hybrid proteins. *Oncogene*, 20 : 2318-2324.
- Warren, S., & Wyatt, P. (2008). *Organic synthesis: the disconnection approach*, 2nd Ed., John Wiley & Sons, Inc., United States.
- Wassman, C. D., Baronio, R., Demir, O., Wallentine, B.D., Chen, C-K., Hall, L. V., *et al.* (2013). Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53. *Nat Commun.*, 4 : 1-9.
- Weber, J. D., Taylor, L. J., Roussel, M. F., Sherr, C. J., & Bar-Sagi, D. (1999). Nucleolar Arf sequesters Mdm2 and activates p53. *Nat. Cell. Biol.*, 1 : 20-26.
- Weinberg, R. A. (2014). *The Biology Of Cancer*, 2nd Ed., Garland Science, Taylor & Francis Group, LLC., New York.

- Weisberg, E., Halilovic, E., Cooke, V. G., Nonami, A., Ren, T., Sanda, T., *et al.* (2015). Inhibition of wild-type p53-expressing AML by novel small molecule HDM2 inhibitor, CGM097. *Mol. Cancer Ther.*, 14 : 2249-2259.
- Weisz, L., Oren, M., & Rotter, V. (2007). Transcription regulation by mutant p53. *Oncogene*, 26 : 2202–2211.
- Willis, A., Jung, E. J., Wakefield, T., & Chen, X. (2004). Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. *Oncogene*, 23 : 2330-2338.
- World Health Organization. (2017). Cancer. diakses dari www.who.int/mediacentre/factsheets/fs297/en/, diakses pada 16 Mei 2017.
- [Wu, G. S.](#), [Burns, T. F.](#), [McDonald, E. R^{3rd}](#), [Jiang, W.](#), [Meng, R.](#), [Krantz, I. D.](#), *et al.* (1997). KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. *Nat. Genet.*, 17 : 141-143.
- Xu, J., Reumers, J., Couceiro, J. R., De Smet, F., Gallardo, R., Rudyak, S., *et al.* (2011). Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. *Nat. Chem. Biol.*, 7 : 285–295.
- Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., *et al.* (2007). Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. *Nature*, 445 : 656-660.
- Yi, L., Lu, C., Hu, W., Sun, Y., & Levine, A.J. (2012). Multiple roles of p53-related pathways in somatic cell reprogramming and stem cell differentiation. *Cancer Res.*, 72 : 5635–5645.
- Ying, Y., & Padanilam, B. J. (2016). Regulation of necrotic cell death p53, PARP1 and Cyclophilin D-overlapping pathways of regulated necrosis?. *Cell. Mol. Life Sci.*, 73 : 2309-2324.
- Yoon, C., Prive, G. G., Goodsell, D. S., & Dickerson, R. E. (1988). Structure of an alternating-B DNA helix and its relationship to A-tract DNA. *PNAS*, 85 : 6332–6336.
- You, L., Liu, H., Huang, J., Xie, W., Wei, J., Ye, X., *et al.* (2017). The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins. *Oncotarget*, 8 : 7777-7790.
- Yu, X., Blanden, A. R., Narayanan, S., Jayakumar, L., Lubin, D., Augeri, D., *et al.* (2014). Small molecule restoration of wildtype structure and function of mutant p53 using a novel a novel zinc-metallochaperone based mechanism. *Oncotarget*, 5 : 8879-8892.
- Yu, X., Vazquez, A., Levine, A. J., & Carpizo, D. R. (2012). Allele-specific p53 mutant reactivation. *Cancer Cell*, 21 : 614-625.

- Yue, X., Zhao, Y., Xu, Y., Zheng, M., Feng, Z., & Hu, W. (2017). Mutant p53 in cancer: accumulation, gain-of-function and therapy. *J. Mol. Biol.*, 429 : 1595-1606.
- Zhang, Q., Bykov, V. J. N., Wiman, K. G., & Zawacka-Pankau, J. (2018). APR-246 reactivates mutant p53 by targeting cysteins 124 and 277. *Cell Death Dis.*, 9 : 1-12.
- Zhu, C., Zhang, C., Zhang, T., Zhang, X., Shen, Q., Tang, B., *et al.* (2016). Rational design of TNF α binding proteins based on the de novo designed protein DS119. *Protein Sci.*, 25 : 2066-2075.